Researchers made strides in pediatric oncology and immunotherapy with several developments: A gene network and AI-driven study identified novel prognostic biomarkers in neuroblastoma, facilitating personalized care. Separately, SKP2’s role in pediatric liver cancer metabolic reprogramming was elucidated, indicating therapeutic potential. Additionally, a multi-epitope nanoplatform was developed to enhance precision tumor targeting for immunotherapy. These advances highlight enhanced molecular targeting strategies in pediatric and solid tumor oncology fields.